Seer, Inc.

you have not received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors at seer.bio. Joining me today from SEER is Omid Farraqzad, Chairman, Chief Executive Officer and Founder, Omid Ostedan, President and Chief Operating Officer, and David Horn, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release to your issue today. For a more complete list and description, please see the risk factors section of the company's quarterly report on form 10Q for the quarter ending June 30, 2021, and in its other filings with the Securities and Exchange Commission. Except as required by law, SEER disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 12, 2021. With that, I would like to turn the call over to Omid.

Thanks, Carrie. I could not be more pleased with the positive trajectory of our business as we continue to build on our strong start to the year. Market response to the Protograph product suite has been strong, and we're engaging with an increasing number of potential customers representing a wide range of end markets across a broad set of geographies. This quarter, we achieved an important commercial milestone, reporting our first revenue related to the sales of the Protograph product suite. Coming into 2021, we set high expectations for our team. Two quarters into the year, we're already ahead of where we thought we would be on a number of fronts. These include, one, the breadth and the depth of our customer pipeline. Two, the overall performance of our product in the hands of customers. Three, the quality and the depth of data generated from our customers, even with relatively small sample sizes that they've used to date. And four, the level of interest from geographies across the globe. I'm encouraged by our continued commercial and operational execution as we move through our three-phase commercialization approach. Building on the collaboration phase, we're currently in limited release phase, and we expect to enter broad release phase in early 2022. We're well underway and making excellent progress in limited release. working with a select set of customers across our key market segments. Our rich funnel of prospective customers continues to expand and mature. We've now shipped and installed the Protograph product suite at multiple limited release sites, including our first international customer. And we're on track to onboard a high single-digit number of limited release customers in 2021. Customers are excited by the performance of the Protograph product suite, the speed with which they're getting up and running, and the data they're generating using their own samples. We're working closely with our customers to demonstrate the power of the proteograph across a wide range of applications, including discovery research, early detection, and biomarker discovery. The early data being generated is affirming that the proteograph is truly a disruptive product that will enable unprecedented access to the proteome with amino acid level resolution. This level of resolution at this scale and speed is only enabled by the ProteoGrav product suite and is essential for understanding the enormous complexity of the proteome and the role specific protein variants play in affecting health and disease. Initial data from our customers and prospective customers has exceeded my expectation and is demonstrating the depth and the breadth of proteomic access that can be easily generated from our platform. OHSU Knight Cancer Institute was the first customer to receive a proteograph product suite late last year. They were able to successfully use data from their pilot project in Q1 to secure funding for prostate cancer study of at least 500 and possibly up to 1,000 samples. This would be at least an order of magnitude greater than any unbiased and deep plasma proteomics study undertaken at the Institute to date. They expect to initiate this project sometime in early fall. Another of our customers, the Broad Institute, used a proteograph product suite to study patient samples that they had previously analyzed using extensive depletion and fractionation workflows for unbiased proteomics. they were aiming to compare the proteograph to the workflow for which data was already known. With the proteograph, they were able to detect low abundant proteins of known significance to the disease area as well as novel candidate biomarkers. This study was completed in a small fraction of the time compared to the original fractionation and depletion workflow. Importantly, the proteograph provided this depth and breadth of proteomic coverage with reproducibility, speed, and ease of use, which will enable much larger studies previously not possible. Another example would be a global CRO with deep expertise in unbiased proteomics who compared a set of samples run in the proteograph product suite with samples previously run under existing deep unbiased proteomic workflow. When comparing the results, the samples processed on the proteograph yielded three times the number of proteins identified compared to their existing workflow, and they were able to detect the majority of FDA-approved biomarkers. While most of these biomarkers are on the higher side of protein abundance scale, they were also able to detect a very large number of low abundant proteins, such as cytokines, that are of interest in disease pathogenesis. This data is another example of the access to the broad dynamic range of the platinum proteome that the proteograph uniquely provides at speed and scale that is unprecedented for unbiased proteomics. It is clear that our customers are eager to move forward to perform large-scale studies using unbiased, deep platinum proteomics with amino acid level resolution. In fact, As customers are seeing the early data, they're expanding their vision of what's possible with the research. And despite the fact that many of the Proteograph product suites were only installed mere weeks or months ago, our customers already have generated compelling data that have resulted in the submission of numerous abstracts for upcoming fall conferences. We expect to see more of this activity, including peer-reviewed publications from SEER and potentially from customers as we head into 2022. We also continue to see significant interest from geographies outside the US, especially from Asia-Pacific region, and in particular China. Given the high level of interest for immediate access to our technology in China, and given the robust performance of the Protograd product suite across our customer sites, we decided to accelerate our entry into this market. We were excited to announce this afternoon that we've established a distribution partnership in China with Enlight Medical. We view China as a significant opportunity for us, and we're delighted to partner with Enlight to enable institutions across the region to access the Proteograph product suite. Enlight is not only a region-specific distributor, but also a partner with significant market access and regulatory expertise across the omics space in China. We believe this expertise will be valuable for our strategy of establishing the Protograph product suite as a critical component of the entire research to clinical continuum in China. As we expand our footprint across an increasing number of customer types with what is already a disruptive product, we're also pushing the envelope with the next set of innovations to further expand the capability of the Protograph product suite. And I expect over the coming months, You will hear more from us about some of these innovations, which include driving up protein coverage, increasing throughput, driving down sample volume, and optimizing use of model organisms. We're absolutely committed to driving a continuous stream of new products and product enhancements that will set the pace for innovation in proteomics. I'm extremely proud of our team, their ingenuity, and the commitment to delivering products that allow us to access the podium in ways never before possible. We're making strong progress across all dimensions of our business. We have reached a significant milestone with our first quarter of product revenue. And while we're at the onset of our journey, and there's still much to be done and to execute, we're accelerating towards the opportunity in front of us. I'm so inspired by the enthusiasm of our customers, their early successes with the Proteograph product suite, their growing ambitions for future projects, and the impact we can have together to enhance our understanding of health and disease. With that, I will now turn the call over to Amid for more detail on our commercial progress.

Thank you. I'm excited by our strong commercial progress as we execute against our objectives for the year. We have an expanding install base of customers across discovery research, translational research, clinical development, and biomarker discovery, to name a few. The Protograph product suite is performing exceptionally well in the hands of customers, enabling them to generate data in ways previously not possible. We are well on our way to meeting our target of high single-digit limited release customers for the year and are expanding our funnel of prospective customers in advance of broad release. We are growing our commercial team and, along with it, our commercial footprint. I am particularly excited we have entered into a distribution agreement with Enlight Medical and are poised to enter China with a partner whose expertise and capabilities will enable us to reach the most impactful customers efficiently and expeditiously. We are taking the right steps to broaden the footprint and impact of our technology and to deliver the type of customer experience that will set us apart from others in our industry. Despite the significant demand for our product, we remain committed to executing our three-phase commercial approach, which we believe is ideal for commercialization of truly disruptive products such as the Proteograph product suite. We are already seeing the benefits of this strategy in action. We have signed multiple limited release customers who have committed to undertake large-scale studies demonstrating the unique power of the Proteograph product suite across a broad range of applications. These are generally multi-month and, in some cases, multi-year agreements, which include a commitment to scaling to large cohort sizes in a relatively short time frame. Given the nature and extent of these commitments, it is important to ensure mutual alignment and fit to create a foundational partnership that can expand over the course of time. As these customers scale their studies, we anticipate the pace of abstract presentations and publications to accelerate and lead to even greater demand for access to the paragraph product suite. As Amit mentioned, a number of these customer-submitted abstracts have already been accepted by leading industry conferences this fall, including ASMS at the end of October. We are delivering a highly differentiated customer experience and enabling our customers to rapidly expand their scientific vision. The experiences of these customers are creating blueprints that others can follow to adopt and rapidly scale the photograph product suite during broad release. A number of our collaboration and limited release customers have begun to serve as reference sites for prospective customers and are willingly sharing their experience and their excitement with others who are interested in accessing the power of the photograph product suite. The relationships, insights, and proof points we're establishing during the first two phases of our commercial release are enhancing our ability to develop applications, fine-tune our approach to enable new markets, and drive the next phase of product adoption. With each new data set generated using the Proteograph product suite, we are seeing the power of this platform in action. Importantly, in every case we're aware of, data generated from the Proteograph product suite is exceeding the data generated using any other approach. Coupled with the ease of use, scalability, and reproducibility of the platform, the Proteograph product suite is demonstrating a level of performance that is unparalleled. I believe this unprecedented access to the proteome will drive novel insights from large-scale, unbiased, and deep proteomic studies using our technology. With that, I will now turn the call over to David for more details around our financials.